BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 21557672)

  • 1. Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine.
    López M; Dorado P; Monroy N; Alonso ME; Jung-Cook H; Machín E; Peñas-Lledó E; Llerena A
    Drug Metabol Drug Interact; 2011; 26(1):5-12. PubMed ID: 21557672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
    Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
    Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy].
    Yamamoto Y; Takahashi Y; Nishimura S; Ikumi Y; Mishima N; Kagawa Y
    Yakugaku Zasshi; 2011; 131(5):809-15. PubMed ID: 21532277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No association between non-bullous skin reactions from lamotrigine and heterozygosity of UGT1A4 genetic variants *2(P24T) or *3(L48V) in Norwegian patients.
    Shirzadi M; Reimers A; Helde G; Sjursen W; Brodtkorb E
    Seizure; 2017 Feb; 45():169-171. PubMed ID: 28068583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients.
    Zeng K; Wang X; Xi Z; Yan Y
    Clin Neurol Neurosurg; 2010 May; 112(4):291-5. PubMed ID: 20071075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A candidate gene study of antiepileptic drug tolerability and efficacy identifies an association of CYP2C9 variants with phenytoin toxicity.
    Depondt C; Godard P; Espel RS; Da Cruz AL; Lienard P; Pandolfo M
    Eur J Neurol; 2011 Sep; 18(9):1159-64. PubMed ID: 21338443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India.
    Rosemary J; Surendiran A; Rajan S; Shashindran CH; Adithan C
    Indian J Med Res; 2006 May; 123(5):665-70. PubMed ID: 16873909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients.
    Argikar UA; Cloyd JC; Birnbaum AK; Leppik IE; Conway J; Kshirsagar S; Oetting WS; Klein EC; Remmel RP
    Epilepsy Res; 2006 Sep; 71(1):54-63. PubMed ID: 16815679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy.
    Lin CJ; Yen MF; Hu OY; Lin MS; Hsiong CH; Hung CC; Liou HH
    Pharmacotherapy; 2008 Jan; 28(1):35-41. PubMed ID: 18154472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between CYP2C9/2C19 polymorphisms and phenytoin maintenance doses in Asian epileptic patients: A systematic review and meta-analysis
.
    Liao K; Liu Y; Ai CZ; Yu X; Li W
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):337-346. PubMed ID: 29628024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].
    Huang Y; Yang JF; Qi XL; Wang YQ; Wang WZ; Chen B
    Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1686-9. PubMed ID: 15569425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical impact of pharmacogenetics on the treatment of epilepsy.
    Löscher W; Klotz U; Zimprich F; Schmidt D
    Epilepsia; 2009 Jan; 50(1):1-23. PubMed ID: 18627414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment.
    Grover S; Gourie-Devi M; Baghel R; Sharma S; Bala K; Gupta M; Narayanasamy K; Varma B; Gupta M; Kaur K; Talwar P; Kaur H; Giddaluru S; Sharma A; Brahmachari SK; Indian Genome Variation Consortium ; Kukreti R
    Pharmacogenomics; 2010 Jul; 11(7):927-41. PubMed ID: 20602612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacogenetics and potential application in personalized medicine.
    Zhou SF; Di YM; Chan E; Du YM; Chow VD; Xue CC; Lai X; Wang JC; Li CG; Tian M; Duan W
    Curr Drug Metab; 2008 Oct; 9(8):738-84. PubMed ID: 18855611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7 -161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children.
    Liu L; Zhao L; Wang Q; Qiu F; Wu X; Ma Y
    Eur J Clin Pharmacol; 2015 Nov; 71(11):1341-7. PubMed ID: 26303110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of UGT1A4 genetic polymorphisms on serum lamotrigine concentrations in Chinese children with epilepsy.
    Wang Q; Liang M; Dong Y; Yun W; Qiu F; Zhao L; Guo Y
    Drug Metab Pharmacokinet; 2015 Jun; 30(3):209-13. PubMed ID: 25922177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting.
    Lee SY; Lee ST; Kim JW
    J Biochem Mol Biol; 2007 May; 40(3):448-52. PubMed ID: 17562299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.
    Chaudhry AS; Urban TJ; Lamba JK; Birnbaum AK; Remmel RP; Subramanian M; Strom S; You JH; Kasperaviciute D; Catarino CB; Radtke RA; Sisodiya SM; Goldstein DB; Schuetz EG
    J Pharmacol Exp Ther; 2010 Feb; 332(2):599-611. PubMed ID: 19855097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population.
    Allabi AC; Gala JL; Horsmans Y
    Pharmacogenet Genomics; 2005 Nov; 15(11):779-86. PubMed ID: 16220110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese.
    Goto S; Seo T; Murata T; Nakada N; Ueda N; Ishitsu T; Nakagawa K
    Ther Drug Monit; 2007 Feb; 29(1):118-21. PubMed ID: 17304159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.